Education and Training
Menu

John (Jack) C. McVey, MD

Jack McVey
Medical School: Cleveland Clinic Lerner College of Medicine Undergraduate: University of Colorado at Boulder

About Dr. McVey

Jack is a PGY3 categorical resident in General Surgery. He graduated summa cum laude from the University of Colorado at Boulder with a Bachelor of Arts in Molecular, Cellular and Developmental Biology. He then received his medical degree from the Cleveland Clinic Lerner College of Medicine with special qualifications in biomedical research. His research has largely focused on liver transplant oncology and liver tumor immunology. His medical school thesis investigated tumor antigen specific T cells towards primary liver cancer in non-alcoholic fatty liver disease. He plans to peruse a career in academic surgical oncology.

Awards

2019
Young Investigator Travel Award, American Transplant Congress

2015
Graduation with Highest Honors, University of Colorado at Boulder

2014
Undergraduate Research Award, Howard Hughes Medical Institute

Research

2019 - 2020
Medical Research Scholar Fellow, National Cancer Institute
Investigation of tumor antigen specific T cells towards primary liver cancer in NAFLD
GI and Thoracic Malignancy Branch
Mentor: Tim F. Greten, MD

2017 - 2020
Medical Student Research, Cleveland Clinic
Development of prognostic scores for liver transplantation of hepatocellular carcinoma
Department of General Surgery
Mentor: Federico N. Aucejo, MD and Kazunari Sasaki, MD

2015 - 2016
Professional Research Assistant, University of Colorado School of Medicine
Understanding alternative splicing in Down syndrome pathology
Department of Biochemistry and Molecular Genetics
Mentor: Rui Zhao, PhD

2012 - 2015
Undergraduate Research, University of Colorado at Boulder
Identification of novel pathways for vascular development within the retina
Department of Molecular, Cellular and Developmental Biology
Mentor: Harald Junge, PhD

Publications

Manuscripts

  1. Lai, M. B., Zhang, C., Shi, J., Johnson, V., Khandan, L., McVey, J.C., . . . Junge, H. J. (2017). TSPAN12 Is a Norrin Co-receptor that Amplifies Frizzled4 Ligand Selectivity and Signaling. Cell Rep, 19(13), 2809-2822.
  2. Firl, D. J., Kimura, S., McVey, J.C., Hashimoto, K., Yeh, H., Miller, C. M., . . . Aucejo, F. N. (2018). Reframingthe approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy. Hepatology, 68(4), 1448-1458.
  3. McVey, J. C., Sasaki, K., Margonis, G. A., Nowacki, A. S., Firl, D. J., He, J., . . . Aucejo, F. N. (2019). The impact of resection margin on overall survival for patients with colon cancer liver metastasis varied according to the primary cancer location. HPB (Oxford), 21(6), 702-710.
  4. Sasaki, K., Firl, D. J., McVey, J. C., Schold, J. D., Iuppa, G., Diago Uso, T., . . . Hashimoto, K. (2019). Elevated Risk of Split-Liver grafts in adult liver Transplantation: Statistical Artifact or Nature of the Beast? Liver Transpl, 25(5), 741-751.
  5. Margonis, G. A., Amini, N., Andreatos, N., Sasaki, K., McVey, J.C., Mirza, M. B., . . . Weiss, M. J. (2019). KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases. HPB (Oxford), 21(11), 1527-1534.
  6. Firl, D. J., Sasaki, K., McVey, J.C., Hupertz, V., Radhakrishnan, K., Fujiki, M., . . . Hashimoto, K. (2019). Improved Survival Following Living Donor Liver Transplantation for Pediatric Acute Liver Failure: Analysis of 20 Years of US National Registry Data. Liver Transpl, 25(8), 1241-1250.
  7. Sasaki, K., McVey, J. C., Firl, D. J., Andreatos, N., Moro, A., Coromina Hernandez, L., . . . Hashimoto, K. (2019). Sufficient hepatic artery flow compensates for poor portal vein flow after liver transplantation in patients with portal vein thrombosis. Clin Transplant, 33(11), e13723.
  8. McVey, J. C., Sasaki, K., Firl, D. J., Fujiki, M., Diago-Uso, T., Quintini, C., . . . Aucejo, F. N. (2019). Prognostication of inflammatory cells in liver transplantation: Is the waitlist neutrophil-to lymphocyte ratio really predictive of tumor biology? Clin Transplant, 33(12), e13743.
  9. Firl, D. J., Sasaki, K., Agopian, V. G., Gorgen, A., Kimura, S., Dumronggittigule, W., . . . McVey, J.C.,… Aucejo, F. N. (2020). Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. Hepatology, 71(2), 569-582.
  10. Diggs, L. P., Ruf, B., Ma, C., Heinrich, B., Cui, L., Zhang, Q., McVey, J.C., . . . Greten, T. F. (2020). CD40 mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma. J Hepatol. [In press].
  11. Heinrich, B., Brown, Z. J., Diggs, L. P., Vormehr, M., Ma, C., Subramanyam, V., . . . McVey, J.C.,… Greten, T. F. (2021). Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology, 160(1), 331-345 e336.
  12. Wabitsch, S., McVey, J. C., Ma, C., Ruf, B., Kamenyeva, O., McCallen, J. D., . . . Greten, T. F. (2021). Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models. iScience, 24(1), 101990.
  13. Sasaki, K., Nair, A., Firl, D. J., McVey, J. C., El-Gazzaz, G., Uso, T. D., . . . Eghtesad, B. (2020). Should We Be Utilizing More Liver Grafts From Pediatric Donation After Circulatory Death Donors? A National Analysis of the SRTR from 2002-2017. Transplantation. [In press].
  14. Sasaki, K., Nair, A., Firl, D. J., McVey, J. C., Moro, A., Diago Uso, T., . . . Hashimoto, K. (2021). Conditional Probability of Graft Survival in Liver Transplantation using Donation after Circulatory Death grafts - a retrospective study. Transpl Int. [In press].

Editorials and Reviews

  1. McVey, J. C., & Sasaki, K. (2020). Combination surgery for hepatocellular carcinoma: slashing and burning to improved survival. Ann Transl Med,8(16), 984.
  2. McVey, J. C., Sasaki, K., & Firl, D. J. (2020). Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepat Oncol, 7(3), HEP26.

Oral Presentations

  1. Sasaki, K., Firl, D. J., Kimura, S., McVey, J. C., Fontan, F., Hashimoto, K., . . . Aucejo, N. F. (2018). HALTHCC as a novel tumor response metric in patients with hepatocellular carcinoma undergoing locoregional therapy while awaiting liver transplantation. HPB, 20, S12-S13.
  2. Mcvey, J. C., Sasaki, K., Firl, D., Miller, C., Hashimoto, K., Quintini, C., & Aucejo, F. (2019). HALT-HCC at the Time of Listing is Superior to Other Allocation Metrics at Predicting Waitlist Dropout; An SRTR Analysis. Am J Transplant, 19, 563-564.

Poster Presentations

  1. Lai, M., McVey, J. C., Zhang, C., Khandan, L., & Junge, H. J. (2015). FEVR-associated mutations in TSPAN12 affect Norrin/Frizzled4 signaling. Investigative Ophthalmology & Visual Science, 56(7), 1094-1094.
  2. McVey, J. C., Lai, M., & Junge, H. J. (2015). Forced interaction between FZD4 and LRP5 induces Norrin/Frizzled4 signaling. Investigative Ophthalmology & Visual Science, 56(7), 53-53.
  3. Acevedo-Moreno, L., Sasaki, K., Firl, D., McVey, J. C., Berber, E., Miller, C., . . . Aucejo, F. (2018). Investigating the breath metabolome as a diagnostic tool for hepatocellular carcinoma in cirrhotic patients. HPB, 20, S82-S83.
  4. McVey, J. C., Sasaki, K., Firl, D. J., Simon, R., Takahashi, H., Pitchaimuthu, M., . . . Aucejo, F. N. (2018). Highest overall neutrophil to lymphocyte ratio on waiting list predicts recurrence-free survival in liver transplantation for hepatocellular carcinoma. HPB, 20, S74.
  5. Simon, R., Sasaki, K., Margonis, G. A., He, J., Acevedo-Moreno, L., Hazem, A., . . . McVey, J.C.,…Pitchaimuthu, M. (2018). Risk factors for very early recurrence of hepatocellular carcinoma: a retrospective review. HPB, 20, S83-S84.
  6. Hernandez, L. C., Sasaki, K., Firl, D., McVey, J. C., Fujiki, M., Aucejo, F., . . . Hashimoto, K. (2018). Sufficient Hepatic Artery Flow Redeems Poor Portal Vein Flow after Liver Transplantation in Patients with Porta Vein Thrombosis. Am J Transplant, 18, 556-557.
  7. McVey, J. C., Sasaki, K., Dan, F., Cristiano, Q., Koji, H., Charles, M., & Federico, A. (2018). The Neutrophil to Lymphocyte Ratio is Confounded by MELD in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation. Am J Transplant, 18, 567-567.
  8. Sasaki, K., Firl, D., McVey, J. C., Iuppa, G., Fujiki, M., Uso, T., . . . Miller, C. (2018). Split/Reduced Liver Grafts in Adult Liver Transplantation, No Longer a Risk for Graft Loss. Am J Transplant,18, 457-457.
  9. Margonis, G. A., Buettner, S., Wagner, D., McVey, J. C., Andreatos, N., Beer, A., . . . Weiss, M. J. (2018). Microsatellite instability in resectable colorectal liver metastasis: An international multi-institutional analysis. Journal of Clinical Oncology, 36(4_suppl), 220-220.
  10. Kusakabe, J., McVey, J. C., Firl, D., Fujiki, M., Aucejo, F., Quintini, C., . . . Sasaki, K. (2019). The Power of Young Donor Liver; Elixir of Life for Sick Liver Transplant Recipient. Am J Transplant, 19, 993-993.
  11. Monge, C., Xie, C., McVey, J. C., Mabry-Hrones, D., Duffy, A., Wood, B. J., & Greten, T. F. (2020). Long term survival of combined ablation therapy and tremelimumab with or without durvalumab in advanced hepatocellular carcinoma. Journal of Clinical Oncology, 38(15_suppl), e16689-e16689.
  12. Sasaki, K., McVey, J. C., Firl, D., Inaba, Y., Kwon, C., Hashimoto, K., & Aucejo, F. (2020). The Oncological Optimal Tacrolimus Target Level after Liver Transplant for Hepatocellular Carcinoma. Am J Transplant, 20, 1065-1065.
  13. Sasaki, K., McVey, J. C., Firl, D., Okubo, K., Fujiki, M., Uso, T., . . . Miller, C. (2019). The Risks Are Not Always The Same; Peak Timing Of Risk In Liver Transplantation. Am J Transplant, 19, 712-712.
  14. McVey, J. C., Ma, C., Diggs, L., Fu, Q., & Greten, T. F. (2020). Platelets inhibit hepatocellular carcinoma growth in the context of nonalcoholic fatty liver disease. Cancer Research, 80(16 Supplement), 991-991.
  15. Wabitsch, S., McVey, J. C., Ma, C., Ruf, B., Diggs, L., Heinrich, B., & Greten, T. F. (2020). Covid-19 treatment candidate hydroxychloroquine impairs tumor response to anti-PD1. Clinical Cancer Research, 26(18 Supplement), S02-02-S02-02.
Share This Page:
Post Tweet